[Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000493:Allopurinol / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality* / Q000628:therapy; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000201:enzymology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000201:enzymology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000201:enzymology; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009113:Muramidase / Q000097:blood / Q000652:urine; D009325:Nausea / Q000139:chemically induced; D011239:Prednisolone / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D003561:Cytarabine; D014750:Vincristine; D000493:Allopurinol; D011239:Prednisolone; D015122:Mercaptopurine; D009113:Muramidase; D008727:Methotrexate
Erfahrungen in der Behandlung unreifzelliger Leukämien mit Cytosin-Arabinosid und Daunorubidomycin.